CMChristian Möbs

Christian Möbs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christian Möbs has a total of 284 co-authors. Here are the top co-authors by number of shared publications:

  • Wolfgang Pfützner

    Clinical & Experimental Allergology, Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany; Allergy Section, Department of Dermatology and Allergology, Allergy Center Hesse, University Hospital Marburg, Marburg, Germany

    19 shared publications
  • Wolfgang Pfützner

    Clinical & Experimental Allergy Department of Dermatology and Allergology Philipps‐Universität Marburg University Hospital Marburg Marburg Germany

    8 shared publications
  • Barbara Bohle

    Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria

    7 shared publications
  • Edzard Spillner

    Immunological Biotechnology, Department of Biological and Chemical Engineering Aarhus University Aarhus Denmark

    7 shared publications
  • Michèle Myriam Rauber

    Clinical & Experimental Allergology, Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany

    7 shared publications
  • Michael Hertl

    Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany

    6 shared publications

Latest Publications

  • Open Access

    T cells in chronic spontaneous urticaria show skin-migratory capacity and endotype-specific differences

    by Sophie C. Hermann Lang, Julia Seidel, Sophia Sachsenberg, Michèle M. Rauber-Ellinghaus, Julia Kurz, Yi-Kui Xiang, Sabine Altrichter, Wolfgang Pfützner, Christian Möbs

  • Open Access

    Nanobody-based IgG simultaneously inhibit the allergenic and enzymatic activity of the dominant honeybee venom allergen

    by Josephine Baunvig Aagaard, Rosaria Gandini, Anne-Sofie Ravn Ballegaard, Bjarke Krogstrup Jensen, Britta Dorn, Amanda Verner Borg Larsen, Anders Lenstrup, Mathias Sønderholm, Michaela Miehe, Wolfgang Pfützner, et al.

    Insect venoms can cause severe allergic reactions, including anaphylaxis, in sensitized individuals. In this study, we aim at preventing anaphylaxis mediated by the most abundant and dominant honeybee venom allergen phospholipase A2 (Api m 1) by blocking its interaction with allergic patient IgE. Therefore, we characterize selected Api m 1-specific nanobodies and identify two high-affinity binders with non-overlapping epitopes. Crystal structures of Api m 1/nanobody complexes reveal diametrically opposed epitopes, one of which involves the active site of Api m 1. Based on this background, we develop mono- and bispecific nanobody-human IgG1 Fc, which exhibits pronounced blocking of IgE binding and effector cell activation in blood samples from honeybee venom allergic patients and reduces systemic reactions in a mouse model of allergen-induced anaphylaxis. This work provides a rationale for using nanobody-based inhibitors to prevent Api m 1-mediated anaphylaxis in honeybee venom allergy.


  • Open Access

    Deep Analysis of Desmoglein-3–Reactive CD4+ T Cells in Pemphigus Vulgaris Reveals a Type 17/Type 2 T-Cell Signature

    by Julia Marschall, Larissa I.A. Schierhofer, Antonio M.S. Santos, Julia Hinterseher, Barbara B. Berg, Christian Möbs, Michael Hertl, Christine L. Zimmer


  • Open Access

    Booster Injection with Birch Pollen Extract Activates B‐Cellular Memory Responses in Patients Having Completed Allergen Immunotherapy

    by Carolin Baum, Christian Möbs, Wolfgang Pfützner

    Allergen immunotherapy (AIT) of patients with IgE‐mediated allergy results in the synthesis of blocking IgG antibodies mediating allergen tolerance. However, as antibody concentrations wane after stopping AIT, tolerance may be lost. The impact of a single booster allergen application on B‐cellular memory in AIT‐treated birch pollen (BP)‐allergic patients was investigated. Twenty‐five patients with BP allergy who finished AIT 3–12 years ago received one allergen injection approximately 4 months prior to the next BP season. We determined peripheral Bet v 1‐specific IgG‐secreting cells (ASC) by ELISPOT analysis and BP‐specific IgG, IgG4, and IgE serum antibodies by ImmunoCAP, and the allergen‐blocking capacity of IgG/IgG4 antibodies by ELIFAB assay. Clinical responses were assessed by visual analog scales. Immunological findings were compared with the primary B cell response of 12 BP‐allergic patients receiving conventional AIT. Bet v 1‐specific ASC significantly increased 2–4 weeks after BP‐injection, accompanied by enhanced levels of both BP‐specific IgG/IgG4 antibodies and allergen‐blocking serum activity. Compared with conventional up‐dosing, a single booster vaccination led to a markedly stronger B cell response after 4 weeks. Allergen booster injection activates B‐cellular memory associated with blocking IgG/IgG4 antibodies, pointing to reinforcement of allergen tolerance after completion of AIT.


  • Open Access

    Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus

    by Dario Didona, Christoph Hudemann, Holger Garn, Daria Krzikalla, Shu-Hung Wang, Julia Hinterseher, Karolin Volkmann, Alexandra Polakova, Anna Zakrzewicz, Simon Feldhoff, et al.

    Background: Pemphigus vulgaris (PV) is a CD4+ T-cell-dependent autoantibody-mediated blistering disease associated with human leucocyte antigen (HLA) class II molecules. IgG autoantibodies against the primary autoantigen desmoglein 3 (Dsg3), a desmosomal adhesion protein on epidermal keratinocytes, cause loss of epidermal cell adhesion. Objectives: To assess the clinical applicability of an innovative nanoparticle platform for the induction of immune tolerance exploiting the natural tolerance potential of liver sinusoidal endothelial cells. An open-label first-in-human study was conducted with TPM203, a mixture of four nanoparticle-coupled immunodominant Dsg3 T-cell peptides. Methods: The efficacy and mechanism of action of TPM203 were first tested in a humanized HLA-DRB1*0402-transgenic PV mouse model. In the clinical phase I trial, TPM203 was administered intravenously in patients with PV with no-to-moderate disease activity in single ascending and multiple doses (three doses of TPM203 two weeks apart). Primary endpoints included safety and tolerability. As a secondary endpoint, pharmacokinetics were assessed. Exploratory endpoints comprised changes in Dsg3-specific and bulk T- and B-cell frequencies, anti-Dsg3 IgG levels and autoantibody-induced keratinocyte dissociation. The trial was registered with EudraCT (2019-001727-12). Results: In the PV mouse model, two administrations of TPM203 significantly reduced anti-Dsg3 IgG. On the cellular level, TPM203 led to a significant decrease in CD4+ T cells in the spleen, accompanied by increased frequencies of regulatory T (Treg) cells. In the clinical trial, the 17 patients with PV enrolled across single- and multiple-dose groups did not experience any serious or severe adverse events, or treatment-related PV worsening. Pharmacokinetics confirmed rapid TPM203 clearance from the circulation. Significant TPM203-induced modulations in bulk lymphocyte subsets included an increase in Treg cells, and reductions in T helper 17.1 and CD27+ memory B cells, when dose groups were combined for analysis. Dsg3-specific T cells were found to be significantly reduced at week 8 following single administration of TPM203. Anti-Dsg3 IgG levels trended downward in the three lower single ascending dose groups, while IgG-induced keratinocyte-dissociating capacity was significantly reduced after multiple doses. Conclusions: Administered for the first time in humans, TPM203 was shown to be a safe and well-tolerated nanoparticle-based therapeutic approach with the potential to promote tolerance induction in PV, justifying further clinical development in this and other autoimmune diseases. An author video to accompany this article is available online.


  • Follicular T-helper cells in bullous pemphigoid: how polarization affects the pathophysiology of B-cell-mediated autoimmune diseases

    by Farzan Solimani, Christian Möbs

    Farzan Solimani, Christian Möbs; Follicular T helper cells in bullous pemphigoid: How polarization affects the pathophysiology of B cell-mediated autoimmun

  • Open Access

    Desmosomal Hyper-Adhesion Affects Direct Inhibition of Desmoglein Interactions in Pemphigus

    by Letyfee Steinert, Michael Fuchs, Anna M. Sigmund, Dario Didona, Christoph Hudemann, Christian Möbs, Michael Hertl, Takashi Hashimoto, Jens Waschke, Franziska Vielmuth


  • Open Access

    A type I interferon regulatory network for human plasmacytoid dendritic cells based on heparin, membrane-bound and soluble BDCA-2

    by Francisco Venegas-Solis, Laura Staliunaite, Elisa Rudolph, Carina Chan-Song Münch, Philipp Yu, Sven-A. Freibert, Takahiro Maeda, Christine L. Zimmer, Christian Möbs, Christian Keller, et al.

    Plasmacytoid dendritic cells (pDCs) produce type I interferons (IFNs) after sensing viral/bacterial RNA or DNA by toll-like receptor (TLR) 7 or TLR9, respectively. However, aberrant pDCs activation can cause adverse effects on the host and contributes to the pathogenesis of type I IFN-related autoimmune diseases. Here, we show that heparin interacts with the human pDCs-specific blood dendritic cell antigen 2 (BDCA-2) but not with related lectins such as DCIR or dectin-2. Importantly, BDCA-2–heparin interaction depends on heparin sulfation and receptor glycosylation and results in inhibition of TLR9-driven type I IFN production in primary human pDCs and the pDC-like cell line CAL-1. This inhibition is mediated by unfractionated and low-molecular-weight heparin, as well as endogenous heparin from plasma, suggesting that the local blood environment controls the production of IFN-α in pDCs. Additionally, we identified an activation-dependent soluble form of BDCA-2 (solBDCA-2) in human plasma that functions as heparin antagonist and thereby increases TLR9-driven IFN-α production in pDCs. Of importance, solBDCA-2 levels in the serum were increased in patients with scrub typhus (an acute infectious disease caused by Orientia tsutsugamushi ) compared to healthy control subjects and correlated with anti-dsDNA antibodies titers. In contrast, solBDCA-2 levels in plasma from patients with bullous pemphigoid or psoriasis were reduced. In summary, this work identifies a regulatory network consisting of heparin, membrane-bound and solBDCA-2 modulating TLR9-driven IFN-α production in pDCs. This insight into pDCs function and regulation may have implications for the treatment of pDCs-related autoimmune diseases.


  • Open Access

    Extracellular vesicles: Messengers of allergic immune responses and novel therapeutic strategy

    by Christian Möbs, Anna Lena Jung

    Extracellular vesicles (EVs) are nanosized particles released by nearly every cell type across all kingdoms of life. As a result, EVs are ubiquitously present in various human body fluids. Composed of a lipid bilayer, EVs encapsulate proteins, nucleic acids, and metabolites, thus playing a crucial role in immunity, for example, by enabling intercellular communication. More recently, there has been increasing evidence that EVs can also act as key regulators of allergic immune responses. Their ability to facilitate cell‐to‐cell contact and to transport a variety of different biomolecules enables active modulation of both innate and adaptive immune processes associated with allergic reactions. A comprehensive understanding of the intricate mechanisms underlying the interactions among allergens, immune cells, and EVs is imperative to develop innovative strategies for controlling allergic responses. This review highlights the recent roles of host cell‐ and bacteria‐derived EVs in allergic diseases, presenting experimental and clinical evidence that underscores their significance. Additionally, the therapeutic potential of EVs in allergy management is outlined, along with the challenges associated with targeted delivery and cargo stability for clinical use. Optimization of EV composition and targeting strategies holds promise for advancing translational applications and establishing EVs as biomarkers or safe therapeutics for assessing allergic reactions. For these reasons, EVs represent a promising avenue for advancing both our understanding and management of allergic immune processes.